HER2
信号通路图
研究领域
抑制剂选择性比较
HER2产品
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| A2007 |
Trastuzumab (anti-HER2)Trastuzumab (anti-HER2)曲妥珠单抗是人源重组的抗体抑制剂，与HER2的胞外区域相结合。 MW:145.53 KD。 |
||
| A2008 |
Pertuzumab (anti-HER2)Pertuzumab (anti-HER2)是一种人源单价克隆抗体，抑制HER2二聚化、破坏HER2与其他HER家族成员结合的能力。MW: 148 KD。 |
||
| S1028 |
Lapatinib (GW-572016) DitosylateLapatinib (GW-572016) Ditosylate是一种有效的EGFR 和 ErbB2抑制剂，在无细胞试验中IC50分别为10.8和9.2 nM。 |
Combination of NVP-AEW541 and lapatinib cooperatively inhibits the growth of NVP-AEW541 resistant murine rhabdomyosarcoma primary cell cultures with Igf1r/Her2 complexes. Cell viability assay for Naïve, untreated (U20325; A) and NVP-AEW541 innately resistant mouse rhabdomyosarcoma primary culture (U44676; B) treated with varying concentrations of NVP-AEW541, lapatinib, or a combination of both. Naïve cells (U20325) were sensitive to NVP-AEW541, but lapatinib had no cooperativity. In contrast, NVP-AEW541 at moderate doses increased cell growth in resistant cell cultures (U44676). However, this paradoxical effect was reduced by the addition of lapatinib, although lapatinib treatment alone had very little effect. C, the NVP-AEW541 resistant primary tumor cell line (U44676) was treated with DMSO, 5 μmol/L lapatinib, 5 μmol/L NVP-AEW541, and a combination of 5 μmol/L NVP-AEW541+lapatinib for 25 minutes and Western blot analysis was done on lysates for p-Igf1r and p-Her2. |
|
| S1011 |
Afatinib (BIBW2992)Afatinib (BIBW2992)不可逆地抑制EGFR/ErbB，包括EGFR(wt)，EGFR(L858R)，EGFR(L858R/T790M)，ErbB2（HER2）和ErbB4（HER4），在无细胞试验中IC50分别为0.5 nM，0.4 nM，10 nM，14 nM和1 nM。 |
Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay. |
|
| S2150 |
Neratinib (HKI-272)Neratinib (HKI-272)是一种高度选择性的HER2和EGFR抑制剂，在无细胞试验中IC50分别为59 nM 和 92 nM；微弱抑制KDR和Src，对Akt，CDK1/2/4，IKK-2，MK-2，PDK1，c-Raf和c-Met没有显著的抑制作用。Phase 3。 |
HER2 mutations V777L, D769H, V842I, G309A induce gain-of-function over HER2 WT in MCF10A mammary epithelial cells. B, HER2 WT, L755S, and del.755–759 cells were grown in Matrigel in the presence of DMSO vehicle (0.5%), neratinib (0.5 μmol/L) or gefitinib (0.5 μmol/L). Phase contrast images were obtained as in A. C, MCF10A-HER2 WT or mutants were seeded in soft agar. After 7 days of growth, they were treated with DMSO vehicle (0.5%), lapatinib (0.5 μmol/L) or neratinib (0.5 μmol/L) for an additional week. Error bars represent 95% highest posterior density intervals. *, Significant difference between the HER2 mutant and HER2 WT; #, the effect of inhibitor treatment was significant (95% highest posterior density interval did not contain 0 for both). D, photomicrographs of the colonies in soft agar on day 12, magnification ×40. |
|
| S1019 |
Canertinib (CI-1033)Canertinib (CI-1033)是一种泛ErbB抑制剂，作用于EGFR和ErbB2，IC50分别为1.5 nM和9.0 nM，但对PDGFR，FGFR，InsR，PKC，和CDK1/2/4等均无抑制活性。Phase 3。 |
(B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 lg). The cells were then treated with Erlotinib (20 lM), Gefitinib (20 lM), Lapatinib (20 lM), CI-1033 (8 lM), LY294002 (20 lM) and Bortezomib (20 lM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times. |
|
| S2111 |
LapatinibLapatinib，以 Lapatinib Ditosylate的形式使用，是一种有效的EGFR和ErbB2抑制剂，在无细胞试验中IC50分别为10.2和9.8 nM。 |
Aberrantly activated PI3K/AKT pathway mediates lapatinib resistance in SK-BR-3-LR cells. (A and B) After drug treatment, phosphorylation of HER2, EGFR, AKT, and ERK1/2 was determined by Western blotting using specific antibodies. |
|
| S1167 |
CP-724714CP-724714是一种有效的，选择性HER2/ErbB2抑制剂，IC50为10 nM，无细胞试验中比作用于EGFR，InsR，IRG-1R，PDGFR，VEGFR2，Abl，Src，c-Met等选择性高640多倍。Phase 2。 |
|
|
| S2192 |
Sapitinib (AZD8931)Sapitinib (AZD8931)是一种可逆的，ATP竞争性EGFR，ErbB2和ErbB3抑制剂，无细胞试验中IC50分别为4 nM，3 nM和4 nM，作用于NSCLC细胞比Gefitinib或Lapatinib更有效，作用于ErbB家族比作用于MNK1和Flt选择性强100倍。Phase 2。 |
|
|
| S1194 |
CUDC-101CUDC-101是一种有效的，多靶点抑制剂，作用于HDAC，EGFR和HER2，IC50分别为4.4 nM， 2.4 nM，和15.7 nM，且抑制I/II型HDACs，但是对III型， Sir-type HDACs没有抑制作用。Phase 1。 |
(a) Decay-corrected microPET/CT scan of MDA-MB-231 tumor bearing mice (n = 4) at 2, 4, and 24 h after i.v. injection of [64Cu]7. The image obtained with coinjection of CUDC-101 (20 mg/kg body weight) is shown for a 24 h blockade. Tumors are indicated by arrows. (b) Decay-corrected region-of interest (ROI) analysis on microPET images of the tumor uptake of [64Cu]7 with or without coinjection of CUDC-101 (20 mg/kg body weight). *, P < 0.05; **, P < 0.01.
|
|
| S2216 |
Mubritinib (TAK 165)Mubritinib (TAK 165)是一种有效的HER2/ErbB2抑制剂，在BT-474细胞中IC50为6 nM；而在BT-474细胞系中对EGFR，FGFR，PDGFR，JAK1，Src和Blk没有抑制作用。Phase 1。 |
(A) Cell proliferationanalysis of NB4 cells 24 h post-Mubritinib treatments(0–1 uM) as measured by MTT proliferation assay. (B) Representative images of cell cycle progression analysis of NB4 cells 24 h post 0.25 uM and 0.5 uM Mubritinib Treatment measured by BrdU flow cytometry. |
|
| S1056 |
AC480 (BMS-599626)AC480 (BMS-599626)是一种选择性的，高效效的HER1和HER2抑制剂，IC50分别为20 nM和30 nM。比对HER4效果强8倍左右，而比对VEGFR2， c-Kit， Lck， MET等的作用强100倍以上。Phase 1。 |
Co-treatments of PI-103 and EGFR inhibitors enhance cytotoxicity in SUM149PT cells. Cells were treated with 0.3 uM of PI-103 in combination with different concentrations (0.1 and 1 uM) of EGFR inhibitors (BMS-599626) for -72 hrs. Cell viability was measured by MTT assay as described in Materials and methods. Data from two independent experiments performed in triplicate are shown as mean+SEM. *P < 0.05; **P < 0.01; ***P < 0.001. |
|
| S1486 |
AEE788 (NVP-AEE788)AEE788 (NVP-AEE788)是一种有效的EGFR和HER2/ErbB2抑制剂，IC50分别为2 nM和6 nM，对VEGFR2/KDR， c-Abl， c-Src，和Flt-1作用效果稍弱，对Ins-R， IGF-1R， PKCα和CDK1没有抑制作用。Phase 1/2。 |
EGFR-SGLT1 interaction is irresponsive to modulators of EGFR’s tyrosine kinase. A: Immunoprecipitation coupled Western blot analysis ofinteractionsbetween EGFR-HA and SGLT1-FlaginHEK293 cells treatedwith EGF or AEE788. EGFR, total EGFR; pEGFR, phosphorylated EGFR; IP, immunoprecipitation; IB, immunoblot. Input, expression levels of indicated exogenous proteinsin HEK293 whole celllysates used for the IP. |
|
| S2752 |
HER2-Inhibitor-1HER2-Inhibitor-1是ARRY-380的类似物。ARRY-380是一种有效的，选择性的HER2抑制剂，IC50为8 nM，等效作用于截短的p95-HER2，作用于HER2比作用于EGFR选择性高500倍。 |
confluent 10cm plates, 24hour FBS starvation, then treatment with compounds at 10nM for 30mins, followed by 5 minutes of 0.05ug/ml of EGF. Pellet was sonicated (setting 5, 5 seconds, twice), then quenched with 2XGSB. Loaded 10ul on AnyKD BioRad gel (20mins at 250V), transfered with BioRad Turbo system for 15 minutes (1.5A, 25V). Blocked with 5% milk for 1 hour at RT. Rocked overnight at 1:1000 in 5% BSA with primary Abs; Anti-rabbit secondary Ab at 1:2000 in 5% milk for 1 hour, developed with Thermo Femto Kit. |
|
| S2784 |
TAK-285TAK-285是一种新型，HER2和EGFR(HER1)双重抑制剂，IC50分别为17 nM和23 nM，作用于HER1/2比作用于HER4选择性高10倍以上，对MEK1/5， c-Met， Aurora B， Lck， CSK等作用效果稍弱。Phase 1。 |
||
| S2816 |
Tyrphostin AG 879Tyrphostin AG 879有效抑制HER2/ErbB2，IC50为1 μM，作用于ErbB2比作用于PDGFR和EGFR选择性高100到500倍。 |
Identification of tyrphostin AG879 as a Kv4.2 channel inhibitor. (A) Chemical structure of AG879. (B) Effect of AG879 on Kv4.2 channels in CHO-K1 cells. AG879 10 μM reduced the Kv4.2-mediated peak current by 31.27 ± 2.4%. The Kv4.2 channel currents were recorded by a depolarization to +40 mV for 300 ms from a holding potential −80 mV. (C) Inhibition by AG879 3, 10 and 20 μM of Kv4.2/KChIP2 co-expressed channels. (D) Concentration-dependent inhibition by AG879 of Kv4.2/KChIP2 channel shown by measuring peak and integral currents. Concentration–response curves for AG879 were fitted to the Hill equation. (E) Reversible inhibition of Kv4.2 by AG879. Maximal inhibition occurred ∼5 min after drug application. (F) Concentration-dependent inhibition by AG879 of Kv4.3 channels. |
|
| S8362 |
Irbinitinib (ARRY-380, ONT-380)ARRY-380 (ONT-380)是一种具有口服活性、可逆的、ATP竞争性的的ErbB2（HER2）小分子抑制剂。在细胞实验中，ARRY-380对ErbB-2和p95 HER2的IC50s分别为8 nM和7 nM，对HER2的选择性是对EGFR的500倍。具有潜在的抗肿瘤活性。 |
||
| S5241 |
Lapatinib ditosylate monohydrateLapatinib ditosylate is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways, used for treatment of solid tumours such as breast and lung cancer. |
||
| S2250 |
(-)-Epigallocatechin Gallate(-)-Epigallocatechin Gallate是从绿茶中分离的一种有效的抗氧化剂Polyphenol flavonoid。抑制telomerase和DNA methyltransferase， 阻滞EGF受体和HER-2受体的激活，抑制脂肪酸合成酶以及谷氨酸脱氢酶的活性。 |
|
|
| S7810 |
Afatinib (BIBW2992) DimaleateAfatinib (BIBW2992) Dimaleate 不可逆地抑制 EGFR/HER2，包括 EGFR(wt)，EGFR(L858R)，EGFR(L858R/T790M) 和 HER2，IC50 分别为0.5 nM，0.4 nM，10 nM 和 14 nM；活性比对Gefitinib抵抗型L858R-T790M EGFR突变体高100倍。 |
Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay. |
|
| S7358 |
Poziotinib (HM781-36B)Poziotinib (HM781-36B)是一种不可逆的泛-HER抑制剂，对HER1，HER2，和HER4的IC50分别为3.2 nM，5.3 nM和23.5 nM。 |
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| A2007 |
Trastuzumab (anti-HER2)Trastuzumab (anti-HER2)曲妥珠单抗是人源重组的抗体抑制剂，与HER2的胞外区域相结合。 MW:145.53 KD。 |
||
| A2008 |
Pertuzumab (anti-HER2)Pertuzumab (anti-HER2)是一种人源单价克隆抗体，抑制HER2二聚化、破坏HER2与其他HER家族成员结合的能力。MW: 148 KD。 |
||
| S1028 |
Lapatinib (GW-572016) DitosylateLapatinib (GW-572016) Ditosylate是一种有效的EGFR 和 ErbB2抑制剂，在无细胞试验中IC50分别为10.8和9.2 nM。 |
Combination of NVP-AEW541 and lapatinib cooperatively inhibits the growth of NVP-AEW541 resistant murine rhabdomyosarcoma primary cell cultures with Igf1r/Her2 complexes. Cell viability assay for Naïve, untreated (U20325; A) and NVP-AEW541 innately resistant mouse rhabdomyosarcoma primary culture (U44676; B) treated with varying concentrations of NVP-AEW541, lapatinib, or a combination of both. Naïve cells (U20325) were sensitive to NVP-AEW541, but lapatinib had no cooperativity. In contrast, NVP-AEW541 at moderate doses increased cell growth in resistant cell cultures (U44676). However, this paradoxical effect was reduced by the addition of lapatinib, although lapatinib treatment alone had very little effect. C, the NVP-AEW541 resistant primary tumor cell line (U44676) was treated with DMSO, 5 μmol/L lapatinib, 5 μmol/L NVP-AEW541, and a combination of 5 μmol/L NVP-AEW541+lapatinib for 25 minutes and Western blot analysis was done on lysates for p-Igf1r and p-Her2. |
|
| S1011 |
Afatinib (BIBW2992)Afatinib (BIBW2992)不可逆地抑制EGFR/ErbB，包括EGFR(wt)，EGFR(L858R)，EGFR(L858R/T790M)，ErbB2（HER2）和ErbB4（HER4），在无细胞试验中IC50分别为0.5 nM，0.4 nM，10 nM，14 nM和1 nM。 |
Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay. |
|
| S2150 |
Neratinib (HKI-272)Neratinib (HKI-272)是一种高度选择性的HER2和EGFR抑制剂，在无细胞试验中IC50分别为59 nM 和 92 nM；微弱抑制KDR和Src，对Akt，CDK1/2/4，IKK-2，MK-2，PDK1，c-Raf和c-Met没有显著的抑制作用。Phase 3。 |
HER2 mutations V777L, D769H, V842I, G309A induce gain-of-function over HER2 WT in MCF10A mammary epithelial cells. B, HER2 WT, L755S, and del.755–759 cells were grown in Matrigel in the presence of DMSO vehicle (0.5%), neratinib (0.5 μmol/L) or gefitinib (0.5 μmol/L). Phase contrast images were obtained as in A. C, MCF10A-HER2 WT or mutants were seeded in soft agar. After 7 days of growth, they were treated with DMSO vehicle (0.5%), lapatinib (0.5 μmol/L) or neratinib (0.5 μmol/L) for an additional week. Error bars represent 95% highest posterior density intervals. *, Significant difference between the HER2 mutant and HER2 WT; #, the effect of inhibitor treatment was significant (95% highest posterior density interval did not contain 0 for both). D, photomicrographs of the colonies in soft agar on day 12, magnification ×40. |
|
| S1019 |
Canertinib (CI-1033)Canertinib (CI-1033)是一种泛ErbB抑制剂，作用于EGFR和ErbB2，IC50分别为1.5 nM和9.0 nM，但对PDGFR，FGFR，InsR，PKC，和CDK1/2/4等均无抑制活性。Phase 3。 |
(B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 lg). The cells were then treated with Erlotinib (20 lM), Gefitinib (20 lM), Lapatinib (20 lM), CI-1033 (8 lM), LY294002 (20 lM) and Bortezomib (20 lM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times. |
|
| S2111 |
LapatinibLapatinib，以 Lapatinib Ditosylate的形式使用，是一种有效的EGFR和ErbB2抑制剂，在无细胞试验中IC50分别为10.2和9.8 nM。 |
Aberrantly activated PI3K/AKT pathway mediates lapatinib resistance in SK-BR-3-LR cells. (A and B) After drug treatment, phosphorylation of HER2, EGFR, AKT, and ERK1/2 was determined by Western blotting using specific antibodies. |
|
| S1167 |
CP-724714CP-724714是一种有效的，选择性HER2/ErbB2抑制剂，IC50为10 nM，无细胞试验中比作用于EGFR，InsR，IRG-1R，PDGFR，VEGFR2，Abl，Src，c-Met等选择性高640多倍。Phase 2。 |
|
|
| S2192 |
Sapitinib (AZD8931)Sapitinib (AZD8931)是一种可逆的，ATP竞争性EGFR，ErbB2和ErbB3抑制剂，无细胞试验中IC50分别为4 nM，3 nM和4 nM，作用于NSCLC细胞比Gefitinib或Lapatinib更有效，作用于ErbB家族比作用于MNK1和Flt选择性强100倍。Phase 2。 |
|
|
| S1194 |
CUDC-101CUDC-101是一种有效的，多靶点抑制剂，作用于HDAC，EGFR和HER2，IC50分别为4.4 nM， 2.4 nM，和15.7 nM，且抑制I/II型HDACs，但是对III型， Sir-type HDACs没有抑制作用。Phase 1。 |
(a) Decay-corrected microPET/CT scan of MDA-MB-231 tumor bearing mice (n = 4) at 2, 4, and 24 h after i.v. injection of [64Cu]7. The image obtained with coinjection of CUDC-101 (20 mg/kg body weight) is shown for a 24 h blockade. Tumors are indicated by arrows. (b) Decay-corrected region-of interest (ROI) analysis on microPET images of the tumor uptake of [64Cu]7 with or without coinjection of CUDC-101 (20 mg/kg body weight). *, P < 0.05; **, P < 0.01.
|
|
| S2216 |
Mubritinib (TAK 165)Mubritinib (TAK 165)是一种有效的HER2/ErbB2抑制剂，在BT-474细胞中IC50为6 nM；而在BT-474细胞系中对EGFR，FGFR，PDGFR，JAK1，Src和Blk没有抑制作用。Phase 1。 |
(A) Cell proliferationanalysis of NB4 cells 24 h post-Mubritinib treatments(0–1 uM) as measured by MTT proliferation assay. (B) Representative images of cell cycle progression analysis of NB4 cells 24 h post 0.25 uM and 0.5 uM Mubritinib Treatment measured by BrdU flow cytometry. |
|
| S1056 |
AC480 (BMS-599626)AC480 (BMS-599626)是一种选择性的，高效效的HER1和HER2抑制剂，IC50分别为20 nM和30 nM。比对HER4效果强8倍左右，而比对VEGFR2， c-Kit， Lck， MET等的作用强100倍以上。Phase 1。 |
Co-treatments of PI-103 and EGFR inhibitors enhance cytotoxicity in SUM149PT cells. Cells were treated with 0.3 uM of PI-103 in combination with different concentrations (0.1 and 1 uM) of EGFR inhibitors (BMS-599626) for -72 hrs. Cell viability was measured by MTT assay as described in Materials and methods. Data from two independent experiments performed in triplicate are shown as mean+SEM. *P < 0.05; **P < 0.01; ***P < 0.001. |
|
| S1486 |
AEE788 (NVP-AEE788)AEE788 (NVP-AEE788)是一种有效的EGFR和HER2/ErbB2抑制剂，IC50分别为2 nM和6 nM，对VEGFR2/KDR， c-Abl， c-Src，和Flt-1作用效果稍弱，对Ins-R， IGF-1R， PKCα和CDK1没有抑制作用。Phase 1/2。 |
EGFR-SGLT1 interaction is irresponsive to modulators of EGFR’s tyrosine kinase. A: Immunoprecipitation coupled Western blot analysis ofinteractionsbetween EGFR-HA and SGLT1-FlaginHEK293 cells treatedwith EGF or AEE788. EGFR, total EGFR; pEGFR, phosphorylated EGFR; IP, immunoprecipitation; IB, immunoblot. Input, expression levels of indicated exogenous proteinsin HEK293 whole celllysates used for the IP. |
|
| S2752 |
HER2-Inhibitor-1HER2-Inhibitor-1是ARRY-380的类似物。ARRY-380是一种有效的，选择性的HER2抑制剂，IC50为8 nM，等效作用于截短的p95-HER2，作用于HER2比作用于EGFR选择性高500倍。 |
confluent 10cm plates, 24hour FBS starvation, then treatment with compounds at 10nM for 30mins, followed by 5 minutes of 0.05ug/ml of EGF. Pellet was sonicated (setting 5, 5 seconds, twice), then quenched with 2XGSB. Loaded 10ul on AnyKD BioRad gel (20mins at 250V), transfered with BioRad Turbo system for 15 minutes (1.5A, 25V). Blocked with 5% milk for 1 hour at RT. Rocked overnight at 1:1000 in 5% BSA with primary Abs; Anti-rabbit secondary Ab at 1:2000 in 5% milk for 1 hour, developed with Thermo Femto Kit. |
|
| S2784 |
TAK-285TAK-285是一种新型，HER2和EGFR(HER1)双重抑制剂，IC50分别为17 nM和23 nM，作用于HER1/2比作用于HER4选择性高10倍以上，对MEK1/5， c-Met， Aurora B， Lck， CSK等作用效果稍弱。Phase 1。 |
||
| S2816 |
Tyrphostin AG 879Tyrphostin AG 879有效抑制HER2/ErbB2，IC50为1 μM，作用于ErbB2比作用于PDGFR和EGFR选择性高100到500倍。 |
Identification of tyrphostin AG879 as a Kv4.2 channel inhibitor. (A) Chemical structure of AG879. (B) Effect of AG879 on Kv4.2 channels in CHO-K1 cells. AG879 10 μM reduced the Kv4.2-mediated peak current by 31.27 ± 2.4%. The Kv4.2 channel currents were recorded by a depolarization to +40 mV for 300 ms from a holding potential −80 mV. (C) Inhibition by AG879 3, 10 and 20 μM of Kv4.2/KChIP2 co-expressed channels. (D) Concentration-dependent inhibition by AG879 of Kv4.2/KChIP2 channel shown by measuring peak and integral currents. Concentration–response curves for AG879 were fitted to the Hill equation. (E) Reversible inhibition of Kv4.2 by AG879. Maximal inhibition occurred ∼5 min after drug application. (F) Concentration-dependent inhibition by AG879 of Kv4.3 channels. |
|
| S8362 |
Irbinitinib (ARRY-380, ONT-380)ARRY-380 (ONT-380)是一种具有口服活性、可逆的、ATP竞争性的的ErbB2（HER2）小分子抑制剂。在细胞实验中，ARRY-380对ErbB-2和p95 HER2的IC50s分别为8 nM和7 nM，对HER2的选择性是对EGFR的500倍。具有潜在的抗肿瘤活性。 |
||
| S5241 |
Lapatinib ditosylate monohydrateLapatinib ditosylate is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways, used for treatment of solid tumours such as breast and lung cancer. |
||
| S2250 |
(-)-Epigallocatechin Gallate(-)-Epigallocatechin Gallate是从绿茶中分离的一种有效的抗氧化剂Polyphenol flavonoid。抑制telomerase和DNA methyltransferase， 阻滞EGF受体和HER-2受体的激活，抑制脂肪酸合成酶以及谷氨酸脱氢酶的活性。 |
|
|
| S7810 |
Afatinib (BIBW2992) DimaleateAfatinib (BIBW2992) Dimaleate 不可逆地抑制 EGFR/HER2，包括 EGFR(wt)，EGFR(L858R)，EGFR(L858R/T790M) 和 HER2，IC50 分别为0.5 nM，0.4 nM，10 nM 和 14 nM；活性比对Gefitinib抵抗型L858R-T790M EGFR突变体高100倍。 |
Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay. |
|
| S7358 |
Poziotinib (HM781-36B)Poziotinib (HM781-36B)是一种不可逆的泛-HER抑制剂，对HER1，HER2，和HER4的IC50分别为3.2 nM，5.3 nM和23.5 nM。 |
沪公网安备 31011502012800号